Ariad Pharmaceuticals Company Profile (NASDAQ:ARIA)

About Ariad Pharmaceuticals (ARIA)

Ariad Pharmaceuticals logoARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ARIA
  • CUSIP: 04033A10
Key Metrics:
  • Previous Close: $23.99
  • 50 Day Moving Average: $21.86
  • 200 Day Moving Average: $14.14
  • 52-Week Range: $4.67 - $23.99
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -57.12
  • P/E Growth: 0.00
  • Market Cap: $N/A
  • Beta: 2.16
  • Net Margins: -16.99%
  • Return on Assets: -5.12%
  • Debt-to-Equity Ratio: -11.28%
  • Current Ratio: 3.17%
  • Quick Ratio: 3.15%

Analyst Ratings

Consensus Ratings for Ariad Pharmaceuticals (NASDAQ:ARIA) (?)
Ratings Breakdown: 1 Sell Rating, 7 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.10)
Consensus Price Target: $16.54 (31.05% downside)

Analysts' Ratings History for Ariad Pharmaceuticals (NASDAQ:ARIA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
1/11/2017SunTrust Banks, Inc.DowngradeBuy -> Hold$24.00N/AView Rating Details
1/10/2017Cowen and CompanyReiterated RatingBuy$16.00N/AView Rating Details
1/10/2017Leerink SwannDowngradeOutperform -> Market PerformN/AView Rating Details
1/10/2017Barclays PLCUpgradeUnderweight -> Equal Weight$9.00 -> $24.00N/AView Rating Details
1/10/2017Jefferies Group LLCDowngradeBuy -> Hold$11.00 -> $24.00N/AView Rating Details
12/10/2016William BlairReiterated RatingOutperform$15.00N/AView Rating Details
12/1/2016JMP SecuritiesReiterated RatingMarket PerformN/AView Rating Details
11/3/2016Deutsche Bank AGInitiated CoverageHold$9.50N/AView Rating Details
10/24/2016JPMorgan Chase & Co.DowngradeNeutral -> Underweight$9.97 -> $7.00N/AView Rating Details
6/20/2016Royal Bank of CanadaReiterated RatingHoldN/AView Rating Details
2/22/2016Goldman Sachs Group IncLower Price Target$7.00 -> $5.00N/AView Rating Details
6/5/2015HC WainwrightReiterated RatingBuyN/AView Rating Details
5/16/2015BMO Capital MarketsReiterated RatingOutperform$14.00N/AView Rating Details
5/16/2015Stifel NicolausReiterated RatingBuyN/AView Rating Details
(Data available from 4/24/2015 forward)


Earnings History for Ariad Pharmaceuticals (NASDAQ:ARIA)
Earnings by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)
Earnings History by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016Q316($0.19)($0.14)$42.93 million$34.30 millionViewListenView Earnings Details
7/28/2016Q216($0.11)$0.59$60.64 million$65.30 millionViewListenView Earnings Details
5/10/2016Q116($0.27)($0.23)$43.06 million$35.60 millionViewListenView Earnings Details
2/23/2016Q415($0.32)($0.32)$44.79 million$36.50 millionViewListenView Earnings Details
11/3/2015Q315($0.23)($0.29)$46.09 million$27.50 millionViewListenView Earnings Details
8/5/2015Q215($0.27)($0.33)$33.24 million$27.80 millionViewListenView Earnings Details
5/7/2015Q115($0.27)($0.28)$27.26 million$23.90 millionViewListenView Earnings Details
2/19/2015Q414($0.12)($0.03)$39.50 million$66.00 millionViewListenView Earnings Details
11/5/2014Q314($0.30)($0.27)$16.50 million$14.70 millionViewListenView Earnings Details
8/6/2014Q214($0.27)($0.30)$13.65 million$12.10 millionViewListenView Earnings Details
5/7/2014Q114($0.32)($0.27)$10.41 million$11.80 millionViewListenView Earnings Details
2/25/2014Q413($0.47)($0.40)$6.31 million$8.28 millionViewListenView Earnings Details
11/6/2013Q313($0.43)($0.36)$16.67 million$16.70 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.40)($0.37)$11.11 million$13.90 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.38)($0.36)$5.01 million$6.40 millionViewListenView Earnings Details
2/25/2013Q4 2012($0.36)($0.36)$78.00 million$0.07 millionViewListenView Earnings Details
11/7/2012Q312($0.32)($0.32)$0.96 million$0.85 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.31)ViewN/AView Earnings Details
5/9/2012($0.23)($0.35)ViewN/AView Earnings Details
2/28/2012($0.20)($0.38)ViewN/AView Earnings Details
11/3/2011$0.02$0.10ViewN/AView Earnings Details
8/2/2011($0.16)($0.36)ViewN/AView Earnings Details
5/5/2011($0.13)($0.29)ViewN/AView Earnings Details
2/17/2011($0.14)($0.25)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Ariad Pharmaceuticals (NASDAQ:ARIA)
2017 EPS Consensus Estimate: ($1.06)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.24)($0.21)($0.23)
Q2 20172($0.23)($0.21)($0.22)
Q3 20172($0.22)($0.22)($0.22)
Q4 20172($0.57)($0.21)($0.39)
(Data provided by Zacks Investment Research)


Dividend History for Ariad Pharmaceuticals (NASDAQ:ARIA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Ariad Pharmaceuticals (NASDAQ:ARIA)
Insider Ownership Percentage: 8.20%
Institutional Ownership Percentage: 86.97%
Insider Trades by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)
Institutional Ownership by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)
Insider Trades by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/9/2017Daniel M BollagVPSell32,000$23.78$760,960.00View SEC Filing  
10/24/2016Timothy P ClacksonInsiderSell19,638$9.56$187,739.28View SEC Filing  
10/3/2016Daniel M BollagVPSell47,384$13.46$637,788.64View SEC Filing  
9/28/2016Timothy P ClacksonInsiderSell8,750$13.98$122,325.00View SEC Filing  
9/22/2016Timothy P ClacksonInsiderSell20,000$13.43$268,600.00View SEC Filing  
9/15/2016Timothy P ClacksonInsiderSell59,369$11.73$696,398.37View SEC Filing  
8/22/2016Timothy P ClacksonInsiderSell19,436$10.47$203,494.92View SEC Filing  
8/12/2016Timothy P ClacksonInsiderSell25,000$10.50$262,500.00View SEC Filing  
7/22/2016Timothy P ClacksonInsiderSell18,286$8.11$148,299.46View SEC Filing  
6/28/2016Hugh M ColeSVPSell6,012$7.05$42,384.60View SEC Filing  
6/22/2016Timothy P ClacksonInsiderSell23,999$7.28$174,712.72View SEC Filing  
6/15/2016Athanese LavidasDirectorSell76,250$8.21$626,012.50View SEC Filing  
6/14/2016Massimo RadaelliDirectorSell108,569$8.25$895,694.25View SEC Filing  
5/23/2016Timothy P ClacksonInsiderSell17,762$8.08$143,516.96View SEC Filing  
5/12/2016Paris PanayiotopoulosCEOBuy26,990$7.41$199,995.90View SEC Filing  
5/2/2016Timothy P ClacksonInsiderSell11,700$7.13$83,421.00View SEC Filing  
4/22/2016Timothy P ClacksonInsiderSell21,409$7.37$157,784.33View SEC Filing  
3/22/2016Timothy P ClacksonInsiderSell23,834$6.58$156,827.72View SEC Filing  
3/21/2016David L BersteinSVPSell2,375$6.47$15,366.25View SEC Filing  
3/21/2016Edward M FitzgeraldVPSell5,417$6.47$35,047.99View SEC Filing  
3/21/2016Frank HaluskaCMOSell3,575$6.47$23,130.25View SEC Filing  
3/19/2016Maria E CantorSVPSell3,575$6.46$23,094.50View SEC Filing  
3/19/2016Martin J DuvallEVPSell4,000$6.47$25,880.00View SEC Filing  
3/19/2016Timothy P ClacksonInsiderSell5,417$6.47$35,047.99View SEC Filing  
3/3/2016Daniel M BollagVPSell9,625$6.11$58,808.75View SEC Filing  
3/3/2016Frank HaluskaCMOSell10,588$6.11$64,692.68View SEC Filing  
3/3/2016Timothy P ClacksonInsiderSell34,672$6.03$209,072.16View SEC Filing  
2/1/2016Edward M. FitzgeraldCFOSell14,667$4.81$70,548.27View SEC Filing  
2/1/2016Maria E. CantorSVPSell16,133$4.82$77,761.06View SEC Filing  
2/1/2016Paris PanayiotopoulosCEOBuy61,099$4.91$299,996.09View SEC Filing  
9/28/2015David L. BersteinSVPSell5,000$6.46$32,300.00View SEC Filing  
9/28/2015Frank HaluskaCMOSell5,500$6.46$35,530.00View SEC Filing  
9/28/2015Timothy P. ClacksoninsiderSell8,750$6.46$56,525.00View SEC Filing  
9/1/2015Maria E CantorSVPSell2,696$9.11$24,560.56View SEC Filing  
8/28/2015Edward M FitzgeraldCFOSell32,858$10.00$328,580.00View SEC Filing  
8/28/2015Maria E CantorSVPSell1,268$10.00$12,680.00View SEC Filing  
7/16/2015David L BersteinSVPSell4,000$8.54$34,160.00View SEC Filing  
7/16/2015Edward M FitzgeraldCFOSell7,000$8.54$59,780.00View SEC Filing  
7/16/2015Frank HaluskaCMOSell4,400$8.54$37,576.00View SEC Filing  
7/16/2015Martin J DuvallEVPSell1,400$8.54$11,956.00View SEC Filing  
5/1/2015Edward M FitzgeraldCFOSell60,000$8.80$528,000.00View SEC Filing  
4/23/2015Timothy P ClacksonInsiderSell123,766$9.50$1,175,777.00View SEC Filing  
3/23/2015Daniel M BollagVPSell7,000$8.72$61,040.00View SEC Filing  
3/23/2015Edward M FitzgeraldCFOSell9,584$8.72$83,572.48View SEC Filing  
3/23/2015Frank HaluskaCMOSell6,875$8.71$59,881.25View SEC Filing  
3/23/2015Maria E CantorSVPSell16,954$8.86$150,212.44View SEC Filing  
3/23/2015Martin J DuvallEVPSell4,834$8.80$42,539.20View SEC Filing  
3/23/2015Timothy P ClacksonInsiderSell32,741$8.88$290,740.08View SEC Filing  
2/12/2015Harvey J M D BergerCEOBuy25,000$6.83$170,750.00View SEC Filing  
2/2/2015Frank HaluskaCMOSell16,134$6.33$102,128.22View SEC Filing  
1/23/2015Harvey J M D BergerCEOBuy25,000$6.17$154,250.00View SEC Filing  
1/14/2015Sarah J SchlesingerDirectorBuy2,600$6.61$17,186.00View SEC Filing  
12/18/2014Harvey J M D BergerCEOBuy25,000$6.35$158,750.00View SEC Filing  
12/17/2014Sarah J SchlesingerDirectorBuy2,600$6.09$15,834.00View SEC Filing  
11/24/2014Maria E CantorSVPSell1,749$7.00$12,243.00View SEC Filing  
11/20/2014Harvey J M D BergerCEOBuy25,000$6.15$153,750.00View SEC Filing  
11/12/2014Sarah J SchlesingerDirectorBuy2,600$6.26$16,276.00View SEC Filing  
9/10/2014Sarah J SchlesingerDirectorBuy5,200$5.73$29,796.00View SEC Filing  
8/15/2014Alexander J DennerDirectorBuy850,000$5.83$4,955,500.00View SEC Filing  
4/2/2014Daniel BollagVPSell2,400$8.22$19,728.00View SEC Filing  
4/2/2014Frank HaluskaCMOSell3,400$8.21$27,914.00View SEC Filing  
4/2/2014Maria CantorSVPSell4,250$8.21$34,892.50View SEC Filing  
4/2/2014Timothy ClacksonInsiderSell6,500$8.21$53,365.00View SEC Filing  
3/21/2014Daniel BollagVPSell2,400$7.89$18,936.00View SEC Filing  
3/21/2014David BersteinSVPSell1,600$7.89$12,624.00View SEC Filing  
3/21/2014Timothy ClacksonInsiderSell6,667$7.89$52,602.63View SEC Filing  
12/19/2013David BersteinVPSell4,500$5.14$23,130.00View SEC Filing  
12/19/2013Frank HaluskaCMOSell5,100$5.14$26,214.00View SEC Filing  
12/19/2013Maria CantorSVPSell6,375$5.14$32,767.50View SEC Filing  
12/19/2013Timothy ClacksonInsiderSell9,750$5.14$50,115.00View SEC Filing  
9/6/2013Timothy P ClacksonInsiderSell8,449$22.00$185,878.00View SEC Filing  
8/14/2013Harvey BergerCEOSell118,759$18.34$2,178,040.06View SEC Filing  
7/18/2013Frank HaluskaCMOSell6,400$19.79$126,656.00View SEC Filing  
7/18/2013Maria E CantorSVPSell8,000$19.79$158,320.00View SEC Filing  
7/18/2013Timothy P ClacksonInsiderSell14,000$19.79$277,060.00View SEC Filing  
7/17/2013Harvey J M D BergerCEOSell199,400$19.84$3,956,096.00View SEC Filing  
6/19/2013Harvey J M D BergerCEOSell11,200$18.00$201,600.00View SEC Filing  
5/15/2013Harvey J M D BergerCEOSell92,498$18.10$1,674,213.80View SEC Filing  
3/26/2013Edward M FitzgeraldCFOSell12,933$18.75$242,493.75View SEC Filing  
3/25/2013Daniel M BollagVPSell12,933$18.87$244,045.71View SEC Filing  
3/25/2013Frank HaluskaCMOSell5,333$18.88$100,687.04View SEC Filing  
3/25/2013Pierre F DodionSVPSell8,133$18.87$153,469.71View SEC Filing  
3/25/2013Timothy P ClacksonInsiderSell19,167$18.87$361,681.29View SEC Filing  
3/13/2013Harvey J M D BergerCEOSell105,400$22.05$2,324,070.00View SEC Filing  
12/21/2012Athanese LavidasDirectorSell10,500$20.31$213,255.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Ariad Pharmaceuticals (NASDAQ:ARIA)
Latest Headlines for Ariad Pharmaceuticals (NASDAQ:ARIA)
DateHeadline logoPositive News Coverage Very Likely to Affect Ariad Pharmaceuticals (ARIA) Share Price - April 22 at 10:22 AM logoAriad Pharmaceuticals, Inc. (ARIA) Given Consensus Recommendation of "Hold" by Brokerages - April 18 at 8:40 AM logoPositive Media Coverage Likely to Impact Ariad Pharmaceuticals (ARIA) Stock Price - April 17 at 12:07 PM logoAriad Pharmaceuticals (ARIA) Flat with Quarterly Loss Projected - April 12 at 11:48 AM logoTocagen IPO Could Garner Significant Investor Attention - April 11 at 8:05 AM logo7-Eleven to Buy Sunoco Shops in Record $3.3 Billion U.S. Bet - April 7 at 3:38 PM logoFormer Ariad CEO joins a familiar face on board of The Medicines Co., hinting at a sale - April 7 at 8:05 AM logoThe Medicines Company Appoints Paris Panayiotopoulos to Its Board of Directors - March 31 at 3:45 PM logoAriad Pharmaceuticals, Inc. (ARIA) Receives Average Recommendation of "Hold" from Analysts - March 31 at 10:29 AM logoAriad Pharmaceuticals, Inc. (ARIA) Receives Average Rating of "Hold" from Analysts - March 24 at 3:19 PM logoAfter Soaring to $150, Can Incyte Stir Up More Upside? - March 15 at 3:49 PM logoTrump???s Immigration Plans an Overhang on Biotech ETFs? - March 2 at 3:51 PM logoBRIEF-Takeda Pharmaceutical completes acquisition of ARIAD Pharmaceuticals - Reuters - February 18 at 3:34 PM logoBRIEF-Takeda Pharmaceutical completes acquisition of ARIAD Pharmaceuticals - February 17 at 6:32 PM logoMedinol Announces Appointment Of Harvey J. Berger, M.D., As Executive Chairman Of Medinol US - February 16 at 8:41 PM logoMedinol Announces Appointment Of Harvey J. Berger, M.D., As Executive Chairman Of Medinol US - February 16 at 8:41 PM logoTakeda Announces Completion of Acquisition of ARIAD Pharmaceuticals (ARIA) - February 16 at 8:41 PM logoARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition o - February 16 at 8:41 PM logoARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition o - February 16 at 8:41 PM logoARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition o - February 16 at 8:41 PM logoTakeda Completes Acquisition of ARIAD Pharmaceuticals, Inc. - Yahoo Finance - February 16 at 3:40 PM logoTakeda Completes Acquisition of ARIAD Pharmaceuticals, Inc. - February 16 at 3:40 PM logoARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits - February 8 at 8:53 PM logoARIAD Files for EU Approval of Lung Cancer Drug Brigatinib - February 7 at 4:31 PM logoAriad Submits Brigatinib Marketing Application (ARIA) - February 7 at 1:44 AM logoARIAD Pharma Reports Submission Of MAA For Brigatinib To EMA - February 7 at 1:44 AM logo7:35 am Ariad Pharm submits a MMA for its ALK inhbiter, brigatinib, to the EMA - February 7 at 1:44 AM logoARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency - February 7 at 1:44 AM


Frequently Asked Questions for Ariad Pharmaceuticals (NASDAQ:ARIA)

What is Ariad Pharmaceuticals' stock symbol?

Ariad Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARIA."

How were Ariad Pharmaceuticals' earnings last quarter?

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) released its earnings results on Thursday, July, 28th. The company reported $0.59 earnings per share for the quarter, topping analysts' consensus estimates of ($0.11) by $0.70. The firm had revenue of $65.30 million for the quarter, compared to the consensus estimate of $60.64 million. The company's revenue was up 133.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.28) EPS.

When will Ariad Pharmaceuticals make its next earnings announcement?

Ariad Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 21st 2017.

Where is Ariad Pharmaceuticals' stock going? Where will Ariad Pharmaceuticals' stock price be in 2017?

10 equities research analysts have issued twelve-month price targets for Ariad Pharmaceuticals' stock. Their forecasts range from $7.00 to $24.00. On average, they anticipate Ariad Pharmaceuticals' share price to reach $16.54 in the next year.

How do I buy Ariad Pharmaceuticals stock?

Shares of Ariad Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Ariad Pharmaceuticals stock cost?

One share of Ariad Pharmaceuticals stock can currently be purchased for approximately $23.99.

Ariad Pharmaceuticals (ARIA) Chart for Monday, April, 24, 2017

This page was last updated on 4/24/2017 by Staff